Monitor the Phase 2b EoE interim data expected in Q4 2026, which is the next major catalyst. The current cash runway into H2 2028 reduces near-term financing risk, but the stock's historical pattern of negative post-filing drift suggests limited upside from this routine quarterly update.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals reported Q2 2026 financial results with a net loss of $14.5M, up from $8.7M a year ago, driven by doubled R&D costs for the RESOLVE Part 2 trial. The company highlighted positive Phase 1b/2a EoE data presented at DDW and a strengthened executive team, while maintaining a cash runway into H2 2028.
Key Financial Metrics
Key Facts
- Net loss of $14.5M for Q2 2026 vs $8.7M in Q2 2025, driven by higher R&D costs.
- Cash and short-term investments of $133.6M as of June 30, 2026, sufficient into H2 2028.
- Phase 1b/2a RESOLVE trial in EoE showed maintained clinical remission and improved tissue health at 36 weeks.
- Appointed Dr. Jeymi Tambiah as CMO and added three industry leaders to the Board.
- EPS of -$0.23 was in line with consensus estimates.
Financial Impact
Net loss increased by $5.8M YoY to $14.5M; cash position of $133.6M provides runway into H2 2028.
Risk Factors
- Clinical trial failure or negative data in upcoming Phase 2b EoE trial.
- Higher-than-expected cash burn rate could necessitate future dilutive financing.
- Restatement of prior financial statements introduces regulatory and investor confidence risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343238 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $7.59 | awaiting T+5 | — | $7.08 (−6.72%) |
Oct 15, 2026 12d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $7.08 (+4.58%) |
Oct 9, 2026 18d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $7.08 (−5.09%) |
Sep 30, 2026 27d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Sep 30, 2026 27d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $7.08 (+4.58%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $7.08 (+6.15%) |
Aug 11, 2026 11w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $7.08 (+9.26%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $7.08 (+8.59%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $7.08 (+6.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers